期 |
栏目 |
标题 |
文件 |
卷 3, 编号 1 (2001) |
Articles |
Novoe v terapii raka molochnoy zhelezy: neoad\"yuvantnaya gormonoterapiya |
|
卷 5, 编号 3 (2003) |
Articles |
Novyy vzglyad na neoad\"yuvantnuyu khimioterapiyu raka molochnoy zhelezy (rol' navel'bina) |
|
卷 5, 编号 4 (2003) |
Articles |
Arimideks (anastrozol) v sravnenii s tamoksifenom v neoad\"yuvantnoy endokrinoterapii bol'nykh rakom molochnoy zhelezy |
|
卷 7, 编号 1 (2005) |
Articles |
Faktory prognoza pri rake molochnoy zhelezy |
|
卷 7, 编号 1 (2005) |
Articles |
Znachenie taksanov v neoad\"yuvantnoy terapii raka molochnoy zhelezy |
|
卷 9, 编号 2 (2007) |
Articles |
Ad\"yuvantnaya endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy |
|
卷 11, 编号 3 (2009) |
Articles |
Predoperatsionnaya (neoad\"yuvantnaya) endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy |
|
卷 15, 编号 4 (2013) |
Articles |
The main markers of the long-term efficiency of neoadjuvant chemotherapy in breast cancer (review of literature) |
|
卷 16, 编号 4 (2014) |
Articles |
Male breast cancer: review of the literature |
|
卷 17, 编号 1 (2015) |
Articles |
Quality of life is the fundamental criterion of the efficacy of targeted therapy in patients with metastatic Her2-positive breast cancer |
|
卷 18, 编号 2 (2016) |
Articles |
New opportunities to improve of duration and quality of life: eribulin in the treatment of patients with advanced breast cancer |
(Rus)
|